Patient Access to Compounded Medical Items

Added a header stamp indicating the bill is at the 3rd Reading Unamended stage in the Senate, dated April 17, 2026.

Changed the version title from 'REVISED' to 'REREVISED' and updated the subtitle to clarify that all amendments adopted in the Second House are included.

Removed the previous version title and subtitle that referenced amendments adopted on Second Reading in the Second House.

Added specific reference to 'licensed resident 503B outsourcing facilities or nonresident 503B outsourcing facilities' to the list of entities covered by the federal law standards.

Reorganized the text to clearly state that the Board shall not adopt rules more restrictive than applicable federal law for the newly included facility types.

Updated the document header to indicate the version is 'Revised' and includes amendments adopted on Second Reading in the Second House, with a specific date of April 16, 2026.

Removed the text defining the bill's application to state-licensed nonresident pharmacies and outsourcing facilities.

Deleted the specific section (Section 4) that outlined amendments to the Colorado Revised Statutes regarding new drug sales.

Added new co-sponsors to the bill.

Updated the bill status header from 'Engrossed' to 'Reengrossed' and revised the summary availability date to March 16, 2026.

Added a new section declaring that federal law recognizes two lawful pathways for compounding human drug products under Sections 503a and 503b.

Reorganized and clarified the list of facilities (resident/nonresident pharmacies and outsourcing facilities) authorized to supply compounded drugs to ensure consistency throughout the statute.

Adjusted line breaks and spacing in the text to improve readability and formatting consistency.